The incretin effect in critically ill patients: a case–control study by Signe Tellerup Nielsen et al.
RESEARCH Open Access
The incretin effect in critically ill patients: a
case–control study
Signe Tellerup Nielsen1*, Susanne Janum1,2, Rikke Krogh-Madsen1, Thomas P. Solomon3 and Kirsten Møller1,4
Abstract
Introduction: Patients admitted to the intensive care unit often develop hyperglycaemia, but the underlying
mechanisms have not been fully described. The incretin effect is reduced in patients with type 2 diabetes. Type 2
diabetes and critical illness have phenotypical similarities, such as hyperglycaemia, insulin resistance and systemic
inflammation. Previous studies have shown beneficial effects of exogenous glucagon-like peptide (GLP)-1 on
glycaemia in critically ill patients, a phenomenon also seen in patients with type 2 diabetes. In this study, we
hypothesised that the incretin effect, which is mediated by the incretin hormones GLP-1 and glucose-dependent
insulinotropic peptide (GIP), is impaired in critically ill patients.
Methods: The incretin effect (i.e., the relative difference between the insulin response to oral and intravenous
glucose administration) was investigated in a cross-sectional case–control study. Eight critically ill patients without
diabetes admitted to a mixed intensive care unit and eight healthy control subjects without diabetes, matched at
group level by age, sex and body mass index, were included in the study. All subjects underwent an oral glucose
tolerance test (OGTT) followed by an intravenous glucose infusion (IVGI) on the next day to mimic the blood
glucose profile from the OGTT. Blood glucose, serum insulin, serum C-peptide and plasma levels of GLP-1, GIP,
glucagon and proinflammatory cytokines were measured intermittently. The incretin effect was calculated as the
increase in insulin secretion during oral versus intravenous glucose administration in six patients. The groups were
compared using either Student’s t test or a mixed model of repeated measurements.
Results: Blood glucose levels were matched between the OGTT and the IVGI in both groups. Compared with
control subjects, proinflammatory cytokines, tumour necrosis factor α and interleukin 6, were higher in patients
than in control subjects. The endogenous response of GIP and glucagon, but not GLP-1, to the OGTT was greater in
patients. The insulin response to the OGTT did not differ between groups, whereas the insulin response to the IVGI
was higher in patients. Consequently, the calculated incretin effect was lower in patients (23 vs. 57 %, p = 0.003).
Conclusions: In critically ill patients, the incretin effect was reduced. This resembles previous findings in patients
with type 2 diabetes.
Trial registration: ClinicalTrials.gov identifier: NCT01347801. Registered on 2 May 2011.
Introduction
Elevated blood glucose is often seen in critically ill patients
without diabetes [1]. The severity of this hyperglycaemia is
correlated to mortality and morbidity in such patients [2],
and normoglycaemia obtained by insulin infusion may re-
duce mortality and morbidity [3, 4]. However, despite the
clear importance of hyperglycaemia to these hard end-
points, the pathophysiological basis of hyperglycaemia in
this context is not fully understood.
Type 2 diabetes and critical illness have similar charac-
teristics, both presenting with insulin resistance (IR) and sys-
temic inflammation, which contribute to the hyperglycaemic
state [5, 6]. In type 2 diabetes, the development of hypergly-
caemia is facilitated by pancreatic β-cell dysfunction, includ-
ing a reduced incretin effect, which is defined as the relative
increase in insulin secretion induced by oral versus intraven-
ous glucose administration. This effect is induced largely by
the intestinal hormones, glucagon-like peptide (GLP)-1 and
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glucose-dependent insulinotropic peptide (GIP) [7, 8]. Un-
derstanding the incretin effect in critical illness is relevant,
given the recent interest in using incretin analogues in the
management of hyperglycaemia in the intensive care unit
(ICU) [9]. Thus, incretin analogues may be associated with a
lower risk of hypoglycaemia [10, 11] than current insulin
treatment regimens [12]. However, our understanding of the
incretin system in ICU patients is insufficient to recommend
routine use of incretin analogues in these patients.
Although type 2 diabetes and critical illness share some
phenotypic characteristics, a major difference is that hyper-
glycaemia in critical illness develops in a matter of days
rather than years. Interestingly, acute experimental hyper-
glycaemia impairs pancreatic β-cell function [13, 14], incre-
tin action [13, 15] and the incretin effect in humans [15].
Additionally, glucose normalisation with insulin treatment
also improves β-cell function and the incretin effect in type
2 diabetes [16–18]. Furthermore, clinical studies by our
group demonstrate that systemic inflammation induced by
tumour necrosis factor (TNF)-α infusion impaired the sup-
pression of GLP-1 on endogenous glucose production [19],
but did not change the incretin effect [20], in healthy
humans. These findings suggest that the incretin effect may
become impaired in critical illness as a consequence of
hyperglycaemia rather than inflammation per se. This no-
tion is supported by evidence that the incretin effect is im-
paired in patients with chronic pancreatitis in the presence
of hyperglycaemia only [21]. Consequently, in the present
study, we hypothesised that the incretin effect in critically
ill patients would be reduced compared with the effect in
age- sex- and body mass index (BMI)-matched healthy con-
trol subjects without diabetes.
Material and methods
Eight patients admitted to a mixed ICU and eight healthy
control subjects without diabetes, who were matched at
group level by age, sex and BMI, were included in the
study (Fig. 1). The study was conducted from April 2012
to May 2013. Informed consent was obtained from the
ICU patients or, when this was not possible, from their
next of kin and their general practitioner according to
Danish law. The control subjects gave oral and written
informed consent to participate. The study was approved
by the Scientific Ethics Committee of the Capital Region
of Denmark (file number H-3-2009-108), approved by
The Danish Data Protection Agency and conducted in ac-
cordance with the Declaration of Helsinki.
Subjects and procedures
Critically ill patients
Eight nondiabetic critically ill patients [haemoglobin A1c
(HbA1c) <6.5 %] were enrolled in the study no more than
72 h after admission to the ICU. Patients were excluded if
they had undergone recent abdominal surgery (except sim-
ple appendectomy), had acute or chronic pancreatitis, had a
history of bariatric surgery, were aged <18 years, or if in-
formed consent could not be obtained. Information about
physical activity level in the 30 days before admission was
obtained from the patient’s next of kin and graded on a
scale from 1–5, with 1 being no physical activity at all and 5
being vigorous physical activity for more the 4 h per week.
On 2 consecutive days, we performed an oral glucose
tolerance test (OGTT; 75 g of glucose in 300 ml of
water) and an isoglycaemic intravenous glucose infusion
(IVGI) (glucose; Fresenius Kabi, Uppsala, Sweden) using
a variable rate designed to match the plasma glucose
profile measured during the OGTT. For the OGTT, the
glucose solution was injected into the stomach through
a nasogastric tube with the patient in an upright position;
for the IVGI, glucose was infused through a central venous
catheter. Six hours before each of these two procedures, all
routine enteral and parenteral nutrition was discontinued.
Fig. 1 Study design. Glucose (50 mg/ml, 25 g in total) was infused intravenously (i.v.) for 150 minutes in the control subjects and for 300 minutes
in the critically ill patients. Circle indicates blood sampled for analysis. Square indicates a continous intervention. BP blood pressure, EDTA
ethylenediaminetetraacetic acid, IVGI intravenous glucose infusion, OGTT oral glucose tolerance test
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To avoid hypoglycaemia induced by fasting, the patients re-
ceived a glucose infusion (total 25 g of glucose) for 5 h until
1 h before the OGTT and IVGI protocol was commenced.
At this time, the glucose and insulin infusions, if any, were
discontinued, and the stomach was emptied via the naso-
gastric tube. Glucose emptying from the stomach during
OGTT was assessed hourly by measuring the gastric con-
tent via the gastric tube. Throughout the procedures, blood
for glucose analysis was obtained from an arterial catheter
located in the radial artery, whereas blood for other ana-
lyses was sampled from a central venous catheter through
an infusion line separated from the glucose infusion.
Healthy control subjects
Eight healthy age-, sex- and BMI-matched control sub-
jects without diabetes (Hb1Ac <6.5 %) were included.
Subjects were excluded if they had a history of recent
abdominal surgery (except for simple appendectomy),
bariatric surgery or cancer or if they had any chronic in-
flammatory disease. Information about physical activity
level in the last 30 days was graded on a scale from 1 to
5, with 1 being no physical activity at all and 5 being vigor-
ous physical activity for more the 4 h per week.
An OGTT and an isoglycaemic IVGI were performed on
2 consecutive days. On each day, subjects reported to the
laboratory after an overnight fast, and baseline blood sam-
ples were collected from an antecubital venous catheter.
For measurement of blood glucose, arterialised blood was
collected from a retrograde venous catheter on the dorsum
of the hand wrapped in a heating blanket. On both study
days, glucose was infused through a cubital venous catheter
on the opposite arm to mimic the pretest glucose infusion
provided to the critically ill patients. This infusion was lim-
ited to a duration of 2½ h (total 25 g of glucose) for logistic
reasons, but it was discontinued at 1 h before the OGTT
or IVGI, as was the case for the critically ill patients. Dur-
ing the OGTT and IVGI, blood samples were obtained ac-
cording to the schedule shown in Fig. 1.
Blood samples
Blood samples from the two groups were collected,
stored and analysed in an identical fashion.
Blood glucose
Arterial blood samples (in patients) and arterialised ven-
ous blood samples (in healthy control subjects) were
analysed during the OGTT and IVGI every 5 minutes
for the first hour and every 10 minutes for the next
hours using a bedside glucose oxidase assay (ABL 725
series; Radiometer, Copenhagen, Denmark).
Insulin and C-peptide
Blood was sampled in serum-separating tubes, stored
upright at room temperature for 20–40 minutes and
centrifuged at 3500 rpm. Serum was removed and stored
at 5 °C until samples were analysed by electrochemical
enzyme-linked immunosorbent assay (ECLIA) (Roche E-
modular; Roche, Basel, Switzerland) within 6 h at the
Department of Clinical Biochemistry, Rigshospitalet,
Copenhagen, Denmark.
GLP-1, GIP and glucagon
Blood was sampled in ethylenediaminetetraacetic acid
(EDTA)-coated tubes with aprotinin (Trasylol; Bayer Health-
Care, Leverkusen, Germany) 5000 IU/ml blood, immediately
centrifuged at 3500 rpm and stored at −80 °C until analysis.
Total GLP-1 was analysed using an ECLIA (Meso Scale Dis-
covery, Rockville, MD, USA) with a detection range of 0.98–
1000 pg/ml and intraassay variation of 1.1–7.6 %. Total GIP
was analysed using an enzyme-linked immunosorbent assay
(EMD Millipore, Billerica, MA, USA) with a detection range
of 4.2–2000 pg/ml, intraassay variation of 3.0–8.8 % and
interassay variation of 1.8–6.1 %. Total glucagon was ana-
lysed using a radioimmunoassay (Electra-Box Diagnostica,
Copenhagen, Denmark) with a detection range of 18.45–
400 pg/ml and intraassay variation of 4.0–6.8 %. Only one
assay was used for glucagon measurements. All samples
were analysed in duplicates on stored plasma, and the
mean value was used for further analysis.
IL-6 and TNF-α
Blood was sampled in EDTA-coated tubes, immediately
centrifuged at 3500 rpm and stored at −80 °C until ana-
lysis. Interleukin (IL)-6 and TNF-α were analysed using
ECLIA (Meso Scale Discovery). For IL-6, the detection
range was 1.58–488 pg/ml, intraassay variation was 5.2–
7.3 % and interassay variation was 4.2–5.5 %. For TNF-α,
the detection range was 0.69–248 pg/ml, intraassay vari-
ation was 6.1–10.1 % and interassay variation 6.2–7.2 %.
All samples were analysed in duplicates on stored plasma,
and the mean value was used for further analysis.
In two of the patients, it was not possible to perform the
IVGI. One patient did not want to participate in the sec-
ond study day, and fasting was not accomplished according
to the protocol in the other patient. In addition, two critic-
ally ill patients did not complete the IVGI to 180 minutes,
one due to transfer to an acute percutaneous coronary
intervention and the other due to termination of treatment
(at 80 min 120 min, respectively). Thus, we present OGTT
data for eight patients and eight control subjects and IVGI
data for six patients and eight control subjects. Data from
the two patients who did not complete the IVGI to 180 mi-
nutes was extrapolated as described below.
Calculations
The incretin effect was calculated as incretin effect =
[incremental area under the curve (iAUC) insulin
OGTT − iAUC insulin IVGI]/iAUC insulin OGTT [8].
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The Matsuda index, a marker of insulin sensitivity,
was calculated as follows [22]:
The homeostatic model assessment (HOMA)-IR, a
marker of IR, was calculated as HOMA-IR = (fasting glu-
cose × fasting insulin)/22.5 [23].
HOMA-β, a marker of β-cell function, was calcu-
lated as HOMA‐β = (20 × fasting insulin)/(fasting glu-
cose − 3.5) [23].
Statistics
The statistical analyses were performed using SAS 9.3
software (SAS Institute, Cary, NC, USA). All statistical
analyses were based on iAUCs during the OGTT and
the IVGI, except for Matsuda index, HOMA-IR and
HOMA-β. iAUC was calculated using the trapezoidal
rule.
Group differences in the incretin effect, the Matsuda
index, HOMA-IR, and HOMA-β were evaluated using
unpaired t tests. Group and trial differences in iAUCs
for glucose, insulin, C-peptide, glucagon, GLP-1, GIP,
TNF-α and IL-6 were evaluated using a mixed model of
repeated measurements adjusted for difference in vari-
ation in the data between the groups. p < 0.05 was con-
sidered significant. If a better fit of normal distribution
was obtained by log transformation, this was performed
before the statistical analysis. Since the number of pa-
tients was small, we also performed nonparametric test-
ing of these variables.
In the text and figures, the incretin effect, Matsuda
index, HOMA-IR, HOMA-β and iAUC of glucose are
given as mean and 95 % confidence interval (CI),
whereas iAUCs of insulin, C-peptide, glucagon, GLP-1,
GIP, TNF-α and IL-6 are given as geometric mean and
95 % CI. The changes over time during OGTT and IVGI
are given as mean or geometric mean and 95 % CI
because the statistics of these measurements were per-
formed with the calculated iAUCs.
The number of participants was determined by a
power calculation based on data from a comparable
study [20] (G*Power 3.0 software) (α = 0.05 and β = 0.2).
Missing data were imputed either by using the average
of the value recorded one time point before and one
time point after the missing value or, if the data were
missing in the beginning or at the end of the OGTT or
IVGI, by multiplying the last available value by the aver-
age percentage change in the other subjects in the group
at that time point. An overview of the missing data is
provided as Additional file 1.
Blood samples were obtained for 300 minutes after
glucose ingestion. Due to missing IVGI data from the
two patients who only partly finished the IVGI, we ana-
lysed only the data from the first 180 minutes in order
to avoid too many imputations.
Results
Subject characteristics
Table 1 summarises the characteristics of the groups.
The patients and the control subjects were matched with
regard to mean age, sex distribution and mean BMI.
Eight patients were included in the study. Individual de-
tails on the eight patients are given in Table 2. Three of
the patients died in the ICU (38 % ICU mortality). The
OGTT and IVGI were performed without any complica-
tions. During the OGTT, as evaluated by aspiration of
gastric contents, the stomach was empty after 60 minutes
in two patients, after 120 minutes in one patient and
after 180 minutes in three patients. In two patients, the
stomach was still not empty after 180 minutes.
Blood glucose
Mean blood glucose was higher in patients than in
control subjects during the OGTT (p = 0.007) (Fig. 2).
Compared with values during the OGTT, blood glucose
during the IVGI was significantly higher in control sub-
jects (p = 0.0158) and significantly lower in patients (p =
0.035).
Matsuda index ¼ 10; 000=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
baseline glucose mean glucoseð Þ  baseline insulin  mean insulinð Þð Þ
p





Mean/median age (yr) 68.8/69.5 66.1/66.5
(64.5–73.5) (64.5–68.5)
Mean/median BMI (kg/m2) 25.0/24.0 25.2/24.7
(21.0–28.0) (22.0–27.4)
Male/female distribution 4/4 4/4






BMI body mass index, HbA1c haemoglobin A1c
Except for male/female distribution, values are mean/median
(interquartile range)
The data on physical activity level are from seven critically ill patients and
eight control subjects
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Male 27 No 2 Ward 2.8 Yes 8.2/7.7(6.4–8.7) None 18.7 3.7 None/
2 Sepsis
(pneumonia)
Female 34 Yes 2 Deceased 4.4 Yes/Yes 9.0/7.7(6.4–10.3) 2 None None/11.2 0.53/1.15
3 Sepsis
(diverticulitis)
Male 23 No 2 Ward 9.0 No 10.4/9.7(9.1–11.3) None None None/ None/
4 Cardiogenic
shock
Female 25 Yes 2 ICU at another
hospital




Male 41 Yes 4 Deceased 5.2 Yes/Yes 8.1/8.4(7.9–9.4) 63 None None/None None/None
6 Sepsis
(pneumonia)
Female 45 Yes 3 Deceased 4.1 Yes/Yes 8.2/7.4(6.6–8.5) None 18.8 None/None 0.04b/0.59
7 Sepsis
(pneumonia)
Male 31 Yes 2 Ward 12.7 No/Yes 7.2/7.6(7.1–8.7) None None None/None None/None
8 Sepsis
(pneumonia)


















APACHE Acute Physiology and Chronic Health Evaluation, ICU intensive care unit, IVGI intravenous glucose infusion, NE norepinephrine, OGTT oral glucose tolerance test, IU International Units
Patients on the ventilator included intubated patients and patients receiving noninvasive ventilation.
aDose equipotent to dexamethasone











As expected, insulin increased during both the OGTT
and the IVGI and was higher during the OGTT than
during the IVGI in both groups (p = 0.038 for patients,
p = 0.0001 for control subjects), corroborating the pres-
ence of an incretin effect. Furthermore, insulin was
higher in patients than in control subjects during the
IVGI (p = 0.045) but not during the OGTT.
Not surprisingly given the insulin response, C-peptide
also increased in both groups and was higher in patients
than in control subjects during the IVGI (p = 0.004) but
not during the OGTT. Interestingly, however, the serum
concentration of C-peptide did not differ between the
OGTT and the IVGI in patients, whereas it was higher
during the OGTT than during the IVGI in the control
subjects (p < 0.0001).
Incretin hormones
Plasma levels of both GIP and GLP-1 rose during the
OGTT in both groups. GLP-1 did not differ between the
groups during the OGTT or the IVGI. However, GLP-1
was higher during the OGTT than during the IVGI in
control subjects (p = 0.0006) but not in patients (Fig. 3).
GIP was higher in patients than in control subjects
Fig. 2 Glucose, insulin and C-peptide. Mean blood glucose (a) was measured every 5 minutes for the first 60 minutes and every 10 minutes for
the next 120 minutes after glucose ingestion. Geometric mean insulin (c) and geometric mean serum C-peptide (e) [with 95 % confidence interval
(CI)] were measured every 20 minutes for 180 minutes after glucose ingestion. Mean iAUC of blood glucose (b), geometric mean iAUC of serum
insulin (d) and geometric iAUC mean of serum C-peptide (f) (95 % CI). *Significant difference between OGTT and IVGI; #significant difference
between groups. iAUC incremental area under the curve, IVGI intravenous glucose infusion, OGTT oral glucose tolerance test
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during the OGTT (p < 0.0001) but not during the IVGI.
Levels were higher during the OGTT than during the
IVGI both in control subjects and in patients.
Glucagon
Plasma glucagon was higher in patients than in control
subjects (p = 0.001 for OGTT, p = 0.046 for IVGT) but
did not change during the OGTT or the IVGI in either
group (Fig. 3).
Cytokines
Plasma levels of the proinflammatory cytokines TNF-α
and IL-6 were higher in the patients than in control sub-
jects (TNF-α, p = 0.015 for OGTT and p = 0.042 for IVGI;
IL-6, p < 0.0001 for OGTT and p < 0.0001 for IVGI),
indicating the presence of systemic inflammation. No dif-
ference occurred during the OGTT and the IVGI in either
group (Fig. 4).
Incretin effect
The incretin effect was less in patients than in control
subjects [23 % (3–43 %) vs. 57 % (45–70 %); p = 0.003]
(Fig. 5).
Insulin sensitivity and fasting insulin resistance
Insulin sensitivity as measured by the Matsuda index
tended to be lower in patients than in control subjects
[2.08 (3.94–7.46) vs. 7.76 (5.09–11.8); p = 0.056). Also, IR
as evaluated by HOMA-IR on the OGTT day was higher
Fig. 3 The incretin hormones and glucagon. Geometric mean plasma GLP-1 (a), geometric mean plasma GIP (c) and geometric mean plasma
glucagon (e) measured 0, 20, 40, 60, 120 and 180 minutes after glucose ingestion, all with 95 % confidence intervals (CIs). Geometric mean iAUC
of plasma GLP-1 (b), geometric mean iAUC of plasma GIP (d) and geometric mean iAUC of plasma glucagon (f) (with 95 % CI). *Significant
difference between OGTT and IVGI; #significant difference between groups. GIP glucose-dependent insulinotropic peptide, GLP glucagon-like
peptide, iAUC incremental area under the curve, IVGI intravenous glucose infusion, OGTT oral glucose tolerance test
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in patients than in control subjects [2.73 (1.1–6.7) vs.
0.87 (0.53–1.44); p = 0.021].
Fasting β-cell function
There was no difference in HOMA-β between the
groups [62.5 (27.1–218.3) in patients vs. 55.0 (33.3–90.9)
in control subjects].
Results of nonparametric testing
Because of the small number of subjects, we performed
additional nonparametric tests of data. This rendered
nonsignificant the difference in blood glucose between
the OGTT and the IVGI in patients (p = 0.0345 in mixed
model, p = 0.0625 by Wilcoxon test), as well as the dif-
ference in serum insulin during IVGI between groups
(p = 0.045 in mixed model, p = 0.0593 by Mann–Whitney
U test). The significance of the remaining analyses
remained unchanged, regardless of whether a parametric
or nonparametric method was used.
Discussion
Despite the well-known association between IR, hyper-
glycaemia and a poor outcome in critically ill patients,
the optimal treatment remains elusive. Thus, although
van den Berghe and coworkers achieved a much im-
proved survival in different intensive care populations
with tight glycaemic control using insulin [3, 4], more
recent studies of insulin treatment in these patients have
shown no such benefit [24, 25]. Whether this is due to a
clinically important increase in hypoglycaemia with insu-
lin or because hyperglycaemia is an epiphenomenon [26]
rather than a mediator of a poor outcome, these discrep-
ancies indicate a need to look beyond the hypergly-
caemia itself and explore the related pathophysiology. In
Fig. 4 TNF-α and IL-6. Geometric mean plasma TNF-α (a) and geometric mean plasma IL-6 (c) measured at baseline and hourly after glucose
ingestion, both with 95 % confidence intervals (CI). Geometric mean iAUC of plasma TNF-α (b) and geometric mean iAUC of plasma IL-6 (d) with
95 % CI. #Significant difference between groups. iAUC incremental area under the curve, IL interleukin, IVGI intravenous glucose infusion, OGTT oral
glucose tolerance test, TNF tumour necrosis factor
Fig. 5 Mean incretin effect with 95 % confidence interval.
#Significant difference between groups
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the present study, while confirming the previously re-
ported presence of hyperglycaemia and IR in critically ill
patients admitted to a multidisciplinary ICU, the major
finding was an impaired incretin effect. Although re-
searchers in previous studies have investigated plasma
levels of incretin hormones, fasting and nonfasting, in
critically ill patients [27–30], this study is, to our know-
ledge, the first investigation of the secretion of incretin
hormones in response to a standardised stimulus. The
incretins, and in particular GLP-1, have gained much
interest during the last few decades as a novel treatment
paradigm for type 2 diabetes [31]. This disease is associ-
ated with a marked reduction in the incretin effect (i.e.,
the physiologically increased insulin secretion that oc-
curs in response to enteral compared with intravenous
administration of nutrients, and which is due to the se-
cretion of incretin hormones by intestinal K and L cells)
[7]. The results of the present study indicate that a simi-
lar reduction is present in critically ill patients.
Insulin levels were similar in patients and control sub-
jects during the OGTT despite the presence of much
higher blood glucose levels in critically ill patients
throughout the study. In fact, patients’ blood glucose
levels failed to return to baseline at 180 minutes after
glucose ingestion. The maximal insulin secretory re-
sponse of the β cell depends on hyperglycaemia and ex-
posure to arginine. Although we did not measure
plasma arginine, levels are reported to be elevated in
critically ill patients in the first week of admission to the
ICU [32, 33]. Adding the level of hyperglycaemia before
the OGTT, it is possible that the β cells were acting
towards the top of their secretory capacity during the
OGTT, secreting the insulin available. The fact that
there was no significant difference in C-peptide concen-
trations during the OGTT and the IVGI in the patients
supports this argument. However, the increase in serum
insulin and in C-peptide, albeit not to the same extent
as insulin, during the OGTT in patients could indicate a
secretory reserve, although large variation in data needs
to be taken into consideration when interpreting the dif-
ference in C-peptide and insulin concentrations.
Both incretin hormones increased during the OGTT.
Furthermore, GIP, but not GLP-1, increased more in the
patients than in the control subjects during the OGTT.
This indicates that L- and K-cell function was preserved
in the patients, even though the resulting levels of GIP
and GLP-1 were insufficient to elicit an appropriate
insulin-secretory response in terms of controlling hyper-
glycaemia. In healthy volunteers, hyperglycaemia induced
by glucose infusion to a level of 10 mmol/L for 24 h
reduces sensitivity to GLP-1 in the β cell [13]. Clinical
studies have shown that infusion of exogenous GLP-1
decreases the glycaemic response to enteral nutrition in
critically ill patients, including those with preexisting type
2 diabetes [34, 35]; however, the sensitivity to exogenous
GIP is impaired, as has also been reported in type 2 dia-
betes [30]. We speculate that the elevated levels of GLP-1
and GIP, in combination with the hyperglycaemia in the
patients, indicate a reduced sensitivity of the β cell to the
insulinotropic effects of the incretins. This suggestion is
supported by in vitro experiments [36].
Glucocorticoids induce hyperglycaemia, decrease the
incretin effect and increase the response of both GLP-1
and GIP [37], and reduce the insulinotropic properties
of GLP-1 and GIP in healthy volunteers [38]. Gluco-
corticoid treatment was used in five of eight patients.
This, as well as elevated level of endogenous cortisol,
which is frequently induced by critical illness [39], may
therefore contribute to the present findings. Plasma
levels of GLP-1, GIP and glucagon were elevated at base-
line in patients (p < 0.05). GLP-1 and glucagon are derived
from the proglucagon molecule, which is produced in the
L cell in the small intestine [7, 40]. This indicates that the
L and K cells were continuously stimulated in these pa-
tients, either because enterally administered nutrients
were still present in the distal part of the small intestine
after 6 h of fasting or due to the action of another local
stimulant, which could be IL-6 [27].
Cytokines and insulin resistance
Critically ill patients exhibit systemic inflammation.
However, systemic inflammation induced by TNF-α in-
fusion in healthy human volunteers does not affect
glucose-stimulated insulin secretion [41] or the incretin
effect [20], despite inducing IR and reducing the sup-
pressive effect of GLP-1 on endogenous glucose produc-
tion [19, 20]. On one hand, in cell studies, TNF-α alone
does not impair insulin secretion, but, when combined
with other proinflammatory cytokines, it induces β-cell
dysfunction [42]. On the other hand, the patients had IR
as evaluated by HOMA-IR. Since TNF-α induces IR in
skeletal muscle [43], systemic elevations of TNF-α in crit-
ically ill patients may cause IR. As an alternative explan-
ation, physical activity levels were lower in the patients
than in control subjects, which could also contribute to IR
in this group [44].
Gastric emptying affects the magnitude of the incretin
effect in healthy subjects and in patients with type 2 dia-
betes [45], and prolonged gastric emptying was observed
in some of the patients, even though this was evaluated
rather crudely by assessing the remaining gastric fluid
contents by aspiration. Thus, the reduced incretin ef-
fect may have been due to or enhanced by the pres-
ence of delayed gastric emptying in our patients.
Furthermore, five of eight patients received gluco-
corticoid treatment in the ICU in the days before and
during the test days; this is also known to reduce the
incretin effect [37].
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Limitations
We included only a small number of patients, which was
primarily due to the very complex setup in the setting of
serious critical illness with the potential for dramatic
changes in clinical presentation. The low number of pa-
tients and the fact that some patients were on steroids
limit the generalisability of the findings. Extrapolation of
data from the IVGI in two patients potentially reduces
the variability in the data. With regard to glycaemic con-
trol, preexisting hyperglycaemia may have contributed to
the impaired incretin effect [46]. The method of choice
to investigate the incretin effect is to conduct the OGTT
and the IVGI on 2 consecutive days [47]. Although we
conducted the studies in the early phase of admission to
the ICU, we cannot rule out the possibility that some of
the patients were already in the recovery phase of their
critical illness. Furthermore, because critical illness is a
dynamic condition, 2 days might not be perfectly com-
parable with regard to severity of disease. The variations
in BMI and age among the patients were slightly greater
than in the control subjects; also, the mean and median
age was higher in the patients. However, we believe that
the matching was sufficient. Due to logistics, the study
protocols in the two groups were not completely identi-
cal with regard to the duration of fasting and the dur-
ation of pretest glucose infusion. Additionally, the site of
blood glucose measurements was arterial blood in the
patients and arterialised venous blood in control sub-
jects. However, we do not believe that these small differ-
ences affected the outcomes significantly.
In the patients, the iAUC of glucose during the OGTT
was slightly higher than that during the IVGI, whereas it
was slightly lower during the OGTT in control subjects.
These differences may have led to an overestimation of
the incretin effect in patients while underestimating it in
control subjects. However, we believe that the large dif-
ference in the incretin effect is very unlikely to be due to
the very small unintended differences in blood glucose
between trials. GLP-1 and GIP levels were analysed in
plasma samples obtained in collecting tubes without
dipeptidyl peptidase (DPP)-4 inhibitor in both groups.
Despite the fact that the blood was obtained in iced
tubes and the samples were centrifuged rapidly, there is
a possibility that some of the GLP-1 and GIP was de-
graded by the enzyme DPP-4 in the tubes before centri-
fugation, leading to potentially lower measured plasma
levels in both groups. HbA1c is slightly higher in pa-
tients, which we believe reflects hyperglycaemia related
to critical illness.
Gastric emptying was evaluated semiquantitatively by
the amount of fluid aspirated from the gastric tube. This
is not the gold standard of measuring gastric emptying,
and we confirmed the position of the gastric tube only
by aspiration of gastric content. Furthermore, gastric
emptying was not measured in the control subjects. Im-
putation of missing data to allow us to calculate the
iAUC was done mainly in the patients. This led to a re-
duction of the variance in that group, which is a limita-
tion in the data. Use of a dual or triple glucose tracer
approach would have allowed determination of hepatic
glucose production during OGTT; however, we did find
significantly higher glucagon levels in the patients, which
might indicate a higher rate of hepatic glycogenolysis in
this group.
Conclusions
This study indicates that a reduced incretin effect ac-
companies IR and hyperglycaemia in critically ill pa-
tients. The results indicate preserved L- and K-cell
function in critically ill patients. Thus, the increase in
GIP and GLP-1 secretion during the OGTT was not suf-
ficient to reduce blood glucose to normal levels.
We suggest that while IR in critically ill patients is a
consequence of systemic inflammation mediated by
TNF-α per se, the impaired incretin effect is not directly
related to inflammation; it more likely occurs secondary
to the development of hyperglycaemia. Delayed gastric
emptying and corticosteroid treatment in critically ill pa-
tients may further reduce the incretin effect. This may
have implications for the treatment of hyperglycaemia in
ICU patients in the future.
Key messages
 The incretin effect may be reduced in critically ill
patients.
 The function of intestinal L cells and K cells seems
to be preserved in critically ill patients.
 The pancreatic β cell may be resistant to the
insulinotropic effects of the incretin hormones in
critically ill patients.
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